Search

Your search keyword '"MESH: Vaccines, Subunit"' showing total 5 results
Start Over Descriptor "MESH: Vaccines, Subunit"
5 results on '"MESH: Vaccines, Subunit"'

1. The global distribution and diversity of protein vaccine candidate antigens in the highly virulent Streptococcus pnuemoniae serotype 1

Author

Cornick, Jennifer E., Tastan Bishop, Özlem, Yalcin, Feyruz, Kiran, Anmol M., Kumwenda, Benjamin, Chaguza, Chrispin, Govindpershad, Shanil, Ousmane, Sani, Senghore, Madikay, du Plessis, Mignon, Pluschke, Gerd, Ebruke, Chinelo, McGee, Lesley, Sigaùque, Beutel, Collard, Jean-Marc, Bentley, Stephen D., Kadioglu, Aras, Antonio, Martin, von Gottberg, Anne, French, Neil, Klugman, Keith P., Heyderman, Robert S., Alderson, Mark, Everett, Dean B., PAGe consortium, Malawi Liverpool Wellcome Trust Clinical Research Programme (MLW), Liverpool School of Tropical Medicine (LSTM)-University of Liverpool-Wellcome Trust-University of Malawi, University of Liverpool, Rhodes University, Grahamstown, The Wellcome Trust Sanger Institute [Cambridge], National Institute for Communicable Diseases [Johannesburg] (NICD), University of the Witwatersrand [Johannesburg] (WITS), Centre de Recherche Médicale et Sanitaire (Niamey, Niger) (CERMES), Réseau International des Instituts Pasteur (RIIP), Medical Research Council Unit The Gambia (MRC), University of Warwick [Coventry], Swiss Tropical and Public Health Institute [Basel], Centers for Disease Control and Prevention [Atlanta] (CDC), Centers for Disease Control and Prevention, Centro de Investigação em Saúde de Manhiça [Maputo, Mozambique] (CISM), London School of Hygiene and Tropical Medicine (LSHTM), Emory University [Atlanta, GA], PATH [Seattle], This work supported by the Bill and Melinda Gates Foundation (Grant No. OPP1023440), Wellcome Trust (Award No. 084679/Z/08/Z), National Research Foundation of South Africa (Grant No. 93690) and the NIH Common Fund Award (H3A Bionet) (Grant No. U41HG006941)., and A full list of PAGe members can be found at http://www.pagegenomes.org/page/consortium

Subjects
Models, Molecular, Vaccination Coverage, Antigenic diversity, MESH: Geography, MESH: Vaccines, Subunit, MESH: Amino Acid Sequence, MESH: Global Health, MESH: Africa, MESH: Virulence, Global Health, Structural diversity, Pneumococcal Vaccines, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, MESH: Pneumococcal Infections, Variant, MESH: Bacterial Proteins, Geography, Virulence, MESH: Asia, Research Support, Non-U.S. Gov't, MESH: Vaccination Coverage, Protein modelling, Antigenic Variation, Europe, Infectious Diseases, Streptococcus pneumoniae, Vaccines, Subunit, Molecular Medicine, MESH: Antigenic Variation, PCV, MESH: Models, Molecular, MESH: Streptococcus pneumoniae, MESH: Pneumococcal Vaccines, Asia, Antigenic profiling, Pneumococcal disease, Serogroup, Article, Pneumococcal Infections, Bacterial Proteins, Research Support, N.I.H., Extramural, Immunology and Microbiology(all), Journal Article, Humans, Multi-valent, Amino Acid Sequence, Alleles, Antigens, Bacterial, MESH: Humans, MESH: Alleles, Public Health, Environmental and Occupational Health, MESH: Serogroup, MESH: South America, South America, veterinary(all), [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, Africa, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Europe, MESH: Antigens, Bacterial
Abstract

International audience; Serotype 1 is one of the most common causes of pneumococcal disease worldwide. Pneumococcal protein vaccines are currently being developed as an alternate intervention strategy to pneumococcal conjugate vaccines. Pre-requisites for an efficacious pneumococcal protein vaccine are universal presence and minimal variation of the target antigen in the pneumococcal population, and the capability to induce a robust human immune response. We used in silico analysis to assess the prevalence of seven protein vaccine candidates (CbpA, PcpA, PhtD, PspA, SP0148, SP1912, SP2108) among 445 serotype 1 pneumococci from 26 different countries, across four continents. CbpA (76%), PspA (68%), PhtD (28%), PcpA (11%) were not universally encoded in the study population, and would not provide full coverage against serotype 1. PcpA was widely present in the European (82%), but not in the African (2%) population. A multi-valent vaccine incorporating CbpA, PcpA, PhtD and PspA was predicted to provide coverage against 86% of the global population. SP0148, SP1912 and SP2108 were universally encoded and we further assessed their predicted amino acid, antigenic and structural variation. Multiple allelic variants of these proteins were identified, different allelic variants dominated in different continents; the observed variation was predicted to impact the antigenicity and structure of two SP0148 variants, one SP1912 variant and four SP2108 variants, however these variants were each only present in a small fraction of the global population (

Published
2017

2. HLA-DR-Restricted Peptides Identified in The Nef Protein Can Induce HIV Type 1-Specific IL-2/IFN-γ-Secreting CD4+And CD4+/CD8+T Cells in Humans after Lipopeptide Vaccination

Author

Jean-Gérard Guillet, Bernard Maillere, Sandra Pouvelle-Moratille, Mathieu Surenaud, Hanne Gahery, Lucie Ourth, Catherine Texier, Céline Igea, Suzanne Figueiredo, Institut Cochin (UMR_S567 / UMR 8104), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Paris Descartes - Paris 5 (UPD5), Commissariat a l'Energie Atomique-Saclay (Protein Engineering and Research Department), Commissariat à l'Energie Atomique-Saclay, [Institut Cochin] Departement Infection, immunité, inflammation, Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Cochin ( UMR_S567 / UMR 8104 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Institut Cochin ( UM3 (UMR 8104 / U1016) ), Université Paris Descartes - Paris 5 ( UPD5 ), Commissariat a l'Energie Atomique-Saclay ( Protein Engineering and Research Department ), and Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS )

Subjects
CD4-Positive T-Lymphocytes, MESH : nef Gene Products, Human Immunodeficiency Virus, Drug Evaluation, Preclinical, MESH: Vaccines, Subunit, HIV Infections, CD8-Positive T-Lymphocytes, Lymphocyte Activation, Gene Products, nef, Epitope, MESH: HIV-1, chemistry.chemical_compound, 0302 clinical medicine, [ SDV.MP ] Life Sciences [q-bio]/Microbiology and Parasitology, MESH: nef Gene Products, Human Immunodeficiency Virus, Cytotoxic T cell, MESH : Drug Evaluation, Preclinical, AIDS Vaccines, 0303 health sciences, ELISPOT, MESH: CD4-Positive T-Lymphocytes, Lipopeptide, MESH: HIV Infections, MESH : CD8-Positive T-Lymphocytes, MESH: CD8-Positive T-Lymphocytes, 3. Good health, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, Infectious Diseases, medicine.anatomical_structure, MESH : CD4-Positive T-Lymphocytes, Vaccines, Subunit, MESH: Drug Evaluation, Preclinical, MESH : Vaccines, Subunit, MESH : HIV-1, medicine.drug, MESH : Gene Products, nef, Interleukin 2, MESH : AIDS Vaccines, T cell, Immunology, MESH: Immunodominant Epitopes, Human leukocyte antigen, Biology, 03 medical and health sciences, MESH : HLA-DR Antigens, MESH: AIDS Vaccines, Virology, MESH : HIV Infections, medicine, Humans, nef Gene Products, Human Immunodeficiency Virus, MESH: Lymphocyte Activation, MESH : Lymphocyte Activation, 030304 developmental biology, MESH: Humans, Immunodominant Epitopes, MESH : Humans, MESH : Immunodominant Epitopes, HLA-DR Antigens, MESH: HLA-DR Antigens, Molecular biology, chemistry, HIV-1, MESH: Gene Products, nef, CD8, 030215 immunology
Abstract

International audience; We screened the Neflaiprotein to identify new HLA-DR-restricted epitopes, because this small protein is expressed early during infection, and specific CD4(+) T cells are critical for effective immunity in HIV-1 infection. We synthesized a set of peptides that covers the sequence of the Nef protein, and performed binding assays using 10 common HLA-DR molecules. We defined four large regions in this protein able to bind very efficiently to eight HLADR molecules. We took advantage of healthy volunteers immunized with an HIV-1 lipopeptide vaccine that contains three of the four HLA DR-restricted regions to investigate their capacities to stimulate T cells. In 11 vaccinated volunteers, typed for their class II molecules, we were able to correlate sequences of the vaccine displaying binding activities to specific HLA-DR molecules and the induction of CD4(+) T cell proliferation. To identify potential HLA-DR epitopes, we synthesized 31 15-mer peptides and showed that 26 bound to one or more HLA-DR molecules. Interestingly, 12 of the 26 15-mer peptides identified are included in the sequence of lipopeptides. We used IFN-gamma ELISPOT and flow cytometer assays to investigate the capacity of these potential CD4(+) T cell epitopes to induce specific T cell responses. We showed that seven of these peptides were able to stimulate HIV-specific T cell responses in five of six tested volunteers. These cells are Nef-specific CD4(+) and CD4(+) CD8(+) T cells secreting IL-2/INF-gamma or IL-2 alone. To conclude, these 26 Nef HLA-DR-restricted peptides could be helpful to better evaluate CD4(+) deficiencies in HIV infection and, for new vaccine designs.

Published
2007

3. Evaluation of protective effect of recombinant dense granule antigens GRA2 and GRA6 formulated in monophosphoryl lipid A (MPL) adjuvant against Toxoplasma chronic infection in mice

Author

Corinne Mercier, Sima Rafati, Karine Musset, Mehdi Assmar, Mohammad-Ali Shokrgozar, M. Reza Sadaie, Marie-France Cesbron-Delauw, Majid Golkar, Laboratoire Adaptation et pathogénie des micro-organismes [Grenoble] (LAPM), and Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)

Subjects
Protozoan Vaccines, medicine.medical_treatment, Protozoan Proteins, Antibodies, Protozoan, Monophosphoryl Lipid A, MESH: Vaccines, Subunit, MESH: Adjuvants, Immunologic, MESH: Lipid A, law.invention, Mice, 0302 clinical medicine, law, MESH: Animals, MESH: Protozoan Proteins, Vaccines, Synthetic, 0303 health sciences, MESH: Cytokines, MESH: Mice, Inbred CBA, MESH: Toxoplasmosis, Animal, biology, MESH: Escherichia coli, MESH: Toxoplasma, Brain, 3. Good health, Vaccination, Lipid A, Infectious Diseases, medicine.anatomical_structure, Vaccines, Subunit, Recombinant DNA, Cytokines, Molecular Medicine, Antibody, Toxoplasma, Adjuvant, MESH: Vaccines, Synthetic, 030231 tropical medicine, Antigens, Protozoan, Spleen, Microbiology, 03 medical and health sciences, MESH: Brain, Adjuvants, Immunologic, Antigen, parasitic diseases, Escherichia coli, medicine, Animals, Humans, MESH: Antibodies, Protozoan, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, MESH: Mice, 030304 developmental biology, MESH: Humans, General Veterinary, General Immunology and Microbiology, MESH: Protozoan Vaccines, Public Health, Environmental and Occupational Health, Toxoplasma gondii, Th1 Cells, biology.organism_classification, Disease Models, Animal, Toxoplasmosis, Animal, MESH: Th1 Cells, Immunology, Mice, Inbred CBA, biology.protein, MESH: Disease Models, Animal, MESH: Antigens, Protozoan
Abstract

To investigate the vaccine potential of both the Toxoplasma GRA2 and GRA6 antigens, the full length recombinant proteins were produced in Escherichia coli, formulated in MPL adjuvant, and used alone and in combination ("mix"), to immunize CBA/J mice. Although high ratios of specific IgG2a/IgG1 were measured against both proteins, only spleen cells from GRA2-immunized mice and mix-immunized mice produced high amounts of both IFN-gamma and IL-2 upon induction with Toxoplasma gondii Excretory-Secretory Antigens. Intra peritoneal challenge with Toxoplasma cysts resulted in significant reduction of brain cysts in GRA2- and in mix-vaccinated mice only. This study shows the protective efficacy of recombinant GRA2 against chronic infection by T. gondii and confirms the utility of MPL adjuvant in enabling a vaccine candidate to induce a protective Th1 immune response.

Published
2007

4. Subunit recombinant vaccine protects against monkeypox

Author

Christopher Trindade, Jay W. Hooper, Aysegul Nalca, Peter Silvera, Genoveffa Franchini, Jean-Michel Heraud, Vaniambadi S. Kalyanaraman, Victor I. Ayala, Irene Kalisz, David Venzon, Barney S. Graham, Wen-Po Tsai, Anna Hryniewicz, Monica Vaccari, Mike Bray, Yvette Edghill-Smith, Meredith Hassett, Jody Manischewitz, Hana Golding, Lisa R. King, Janie Parrino, National Cancer Institute [Bethesda] (NCI-NIH), National Institutes of Health [Bethesda] (NIH), Advanced Bioscience Laboratories (ABL), National Institute of Allergy and Infectious Diseases [Bethesda] (NIAID-NIH), U.S. Food and Drug Administration (FDA), University of Bialystok, U.S. Army Medical Research Institute of Infectious Diseases, Southern Research Institute [Birmingham, USA], This work was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research, the National Institute of Allergy and Infectious Diseases Intramural Biodefense Research Award program, and and National Institutes of Health Contract N01-AI-15451.

Subjects
MESH: Monkeypox, viruses, MESH: Vaccines, Subunit, MESH: Amino Acid Sequence, Antibodies, Viral, law.invention, Dryvax, chemistry.chemical_compound, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, law, Immunology and Allergy, MESH: Animals, Monkeypox virus, Smallpox vaccine, Antigens, Viral, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, 0303 health sciences, Vaccines, Synthetic, virus diseases, 3. Good health, Titer, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Vaccines, Subunit, Recombinant DNA, [SDV.IMM]Life Sciences [q-bio]/Immunology, MESH: Antigens, Viral, Smallpox Vaccine, MESH: Vaccines, Synthetic, Immunology, Molecular Sequence Data, Biology, Virus, MESH: Macaca mulatta, 03 medical and health sciences, Monkeypox, MESH: Viral Vaccines, medicine, Smallpox, Animals, Amino Acid Sequence, 030304 developmental biology, MESH: Molecular Sequence Data, 030306 microbiology, [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, Viral Vaccines, medicine.disease, MESH: Smallpox Vaccine, Virology, Macaca mulatta, MESH: DNA, Viral, Disease Models, Animal, MESH: Monkeypox virus, chemistry, DNA, Viral, MESH: Disease Models, Animal, [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology, Vaccinia, MESH: Antibodies, Viral
Abstract

The smallpox vaccine Dryvax, a live vaccinia virus (VACV), protects against smallpox and monkeypox, but is contraindicated in immunocompromised individuals. Because Abs to VACV mediate protection, a live virus vaccine could be substituted by a safe subunit protein-based vaccine able to induce a protective Ab response. We immunized rhesus macaques with plasmid DNA encoding the monkeypox orthologs of the VACV L1R, A27L, A33R, and B5R proteins by the intradermal and i.m. routes, either alone or in combination with the equivalent recombinant proteins produced in Escherichia coli. Animals that received only DNA failed to produce high titer Abs, developed innumerable skin lesions after challenge, and died in a manner similar to placebo controls. By contrast, the animals vaccinated with proteins developed moderate to severe disease (20–155 skin lesions) but survived. Importantly, those immunized with DNA and boosted with proteins had mild disease with 15 or fewer lesions that resolved within days. DNA/protein immunization elicited Th responses and binding Ab titers to all four proteins that correlated negatively with the total lesion number. The sera of the immunized macaques recognized a limited number of linear B cell epitopes that are highly conserved among orthopoxviruses. Their identification may guide future efforts to develop simpler, safer, and more effective vaccines for monkeypox and smallpox.

Published
2006

5. Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines

Author

Julien, Taieb, Nathalie, Chaput, Noël, Schartz, Stéphan, Roux, Sophie, Novault, Cédric, Ménard, François, Ghiringhelli, Magali, Terme, Antoine F, Carpentier, Guillaume, Darrasse-Jèze, Guillaume, Darrasse-Jèse, François, Lemonnier, Laurence, Zitvogel, Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Gustave Roussy (IGR), Service d'Hépato-Gastro-Entérologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Mort cellulaire et cancer, Université de Bourgogne (UB)-IFR100 - Structure fédérative de recherche Santé-STIC-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Neurologie [CHU Pitié-Salpêtrière], IFR70-CHU Pitié-Salpêtrière [AP-HP], Biologie et thérapeutique des pathologies immunitaires (BTPI), Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), Immunité Cellulaire Antivirale, Institut Pasteur [Paris], This work is supported by a Poste d’accueil Institut National de la Santé et de la Recherche Médicale and Assistance Publique Hopitaux de Paris (to J.T.) and is supported by a European fellowship in the QLRT-2001-00093 and by Association de Recherche contre le Cancer (to N.C.). This work has also been supported by the EC ALLOSTEM grant, by DC THERA European grant, by the Association de Recherche contre le Cancer, and by the LIGUE LABELLISEE française contre le Cancer cancéropôle, Ile de France., Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Pasteur [Paris] (IP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Novault, Sophie

Subjects
medicine.medical_treatment, [SDV]Life Sciences [q-bio], Melanoma, Experimental, MESH: Vaccines, Subunit, MESH: Adjuvants, Immunologic, CD8-Positive T-Lymphocytes, Pharmacology, MESH: Antineoplastic Agents, Alkylating, Immunotherapy, Adoptive, T-Lymphocytes, Regulatory, MESH: Mice, Knockout, MESH: Cancer Vaccines, Mice, 0302 clinical medicine, MESH: Cytoplasmic Vesicles, polycyclic compounds, Immunology and Allergy, MESH: Animals, IL-2 receptor, Cells, Cultured, Mice, Knockout, Mice, Inbred BALB C, MESH: Dendritic Cells, FOXP3, MESH: CD8-Positive T-Lymphocytes, 3. Good health, Killer Cells, Natural, [SDV] Life Sciences [q-bio], MESH: Melanoma, Experimental, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Vaccines, Subunit, MESH: Immunotherapy, Adoptive, Female, hormones, hormone substitutes, and hormone antagonists, MESH: Cells, Cultured, MESH: Killer Cells, Natural, MESH: Mice, Transgenic, T cell, Immunology, MESH: Mice, Inbred BALB C, Mice, Transgenic, Biology, Major histocompatibility complex, Cancer Vaccines, Exosome, 03 medical and health sciences, Adjuvants, Immunologic, medicine, Animals, Humans, Antineoplastic Agents, Alkylating, Cyclophosphamide, MESH: Mice, MESH: Humans, MESH: T-Lymphocytes, Regulatory, Cytoplasmic Vesicles, MESH: Cyclophosphamide, Dendritic Cells, Immunotherapy, Microvesicles, CTL, biology.protein, MESH: Female, 030215 immunology
Abstract

Dendritic cell-derived exosomes (DEX) are nanomeric vesicles harboring MHC/peptide complexes capable of promoting primary T cell responses and tumor rejection in the presence of adjuvants. In this study, we show that, in the absence of adjuvants, DEX mediate potent Ag-dependent antitumor effects against preestablished tumors in mice pretreated with immunopotentiating dosing of cyclophosphamide. Cyclophosphamide could 1) abolish the suppressive function of CD4+CD25+Foxp3+ regulatory T cells, 2) markedly enhance the magnitude of secondary but not primary CTL responses induced by DEX vaccines, 3) synergize with DEX in therapy but not prophylaxis tumor models. Therefore, therapeutic vaccines such as DEX aimed at boosting tumor-primed effector T cells could benefit procedures that minimize the effects of CD4+CD25+ regulatory T cells.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results